Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
0.00 (0.00%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.94 - 3.12
52 week 1.69 - 5.84
Open 3.03
Vol / Avg. 81,964.00/239,207.00
Mkt cap 20.00M
P/E     -
Div/yield     -
EPS -1.63
Shares 6.98M
Beta 1.36
Inst. own 6%
Aug 10, 2016
Q2 2016 Opexa Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 12, 2016
Q1 2016 Opexa Therapeutics Inc Earnings Call
May 12, 2016
Q1 2016 Opexa Therapeutics Inc Earnings Release
Mar 15, 2016
Q4 2015 Opexa Therapeutics Inc Earnings Call
Mar 15, 2016
Q4 2015 Opexa Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -297.46% -470.18%
Operating margin -297.76% -473.10%
EBITD margin - -459.30%
Return on average assets -66.48% -91.68%
Return on average equity -100.62% -140.95%
Employees 26 -
CDP Score - -


2635 Technology Forest Blvd
THE WOODLANDS, TX 77381-3905
United States - Map
+1-281-2729331 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company's product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Director
Age: 52
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 62
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 54
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 59
Bio & Compensation  - Reuters